[1] Stumpf C, Kaemmerer D, Neubauer E, Sanger J, Schulz S, Lupp A. Somatostatin and CXCR4 expression patterns in adenocarcinoma and squamous cell carcinoma of the lung relative to small cell lung cancer. 2018;144(10):1921-1932.
[2] Zhao H, Ren D, Liu H, Chen J. Comparison and discussion of the treatment guidelines for small cell lung cancer. 2018;9(7):769-774.
[3] Bunn PA, Jr., Minna JD, Augustyn A, Gazdar AF, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier JT, Byers LA, Wynes MW, McFadden DG, MacPherson D, Hann CL, Farago AF, Dive C, Teicher BA, Peacock CD, Johnson JE, Cobb MH, Wendel HG, Spigel D, Sage J, Yang P, Pietanza MC, Krug LM, Heymach J, Ujhazy P, Zhou C, Goto K, Dowlati A, Christensen CL, Park K, Einhorn LH, Edelman MJ, Giaccone G, Gerber DE, Salgia R, Owonikoko T, Malik S, Karachaliou N, Gandara DR, Slotman BJ, Blackhall F, Goss G, Thomas R, Rudin CM, Hirsch FR. Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016;11(4):453-474.
[4] Byers LA, Rudin CM. Small cell lung cancer: where do we go from here? Cancer. 2015;121(5):664-672.
[5] Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow LQ, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan T, Koczywas M, Loo BW, Jr., Merritt RE, Moran CA, Niell HB, O'Malley J, Patel JD, Ready N, Rudin CM, Williams CC, Jr., Gregory K, Hughes M. Small cell lung cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2013;11(1):78-98.
[6] Pillai RN, Owonikoko TK. Small cell lung cancer: therapies and targets. Seminars in oncology. 2014;41(1):133-142.
[7] Waqar SN, Morgensztern D. Treatment advances in small cell lung cancer (SCLC). Pharmacology & therapeutics. 2017;180:16-23.
[8] Hendriks LEL, Menis J, Reck M. Prospects of targeted and immune therapies in SCLC. Expert review of anticancer therapy. 2018:1-17.
[9] Wang Z, Fu S, Zhao J, Zhao W, Shen Z, Wang D, Duan J, Bai H, Wan R, Yu J, Wang S, Chen H, Chen B, Wang L, Wang J. Transbronchoscopic patient biopsy-derived xenografts as a preclinical model to explore chemorefractory-associated pathways and biomarkers for small-cell lung cancer. Cancer letters. 2019;440-441:180-188.
[10] Duan Y, Huo D, Gao J, Wu H, Ye Z, Liu Z, Zhang K, Shan L, Zhou X, Wang Y, Su D, Ding X, Shi L, Wang Y, Shang Y, Xuan C. Ubiquitin ligase RNF20/40 facilitates spindle assembly and promotes breast carcinogenesis through stabilizing motor protein Eg5. Nature communications. 2016;7:12648.
[11] He J, Zhang Z, Ouyang M, Yang F, Hao H, Lamb KL, Yang J, Yin Y, Shen WH. PTEN regulates EG5 to control spindle architecture and chromosome congression during mitosis. Nature communications. 2016;7:12355.
[12] Scarabelli G, Grant BJ. Kinesin-5 allosteric inhibitors uncouple the dynamics of nucleotide, microtubule, and neck-linker binding sites. Biophysical journal. 2014;107(9):2204-2213.
[13] Liu Y, Zhang Z, Liang H, Zhao X, Liang L, Wang G, Yang J, Jin Y, McNutt MA, Yin Y. Protein Phosphatase 2A (PP2A) Regulates EG5 to Control Mitotic Progression. Scientific reports. 2017;7(1):1630.
[14] Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, Habuka M, Tahmasebpoor S, Danielsson A, Edlund K, Asplund A, Sjostedt E, Lundberg E, Szigyarto CA, Skogs M, Takanen JO, Berling H, Tegel H, Mulder J, Nilsson P, Schwenk JM, Lindskog C, Danielsson F, Mardinoglu A, Sivertsson A, von Feilitzen K, Forsberg M, Zwahlen M, Olsson I, Navani S, Huss M, Nielsen J, Ponten F, Uhlen M. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Molecular & cellular proteomics : MCP. 2014;13(2):397-406.
[15] Imai T, Oue N, Nishioka M, Mukai S, Oshima T, Sakamoto N, Sentani K, Matsusaki K, Yoshida K, Yasui W. Overexpression of KIF11 in Gastric Cancer with Intestinal Mucin Phenotype. Pathobiology : journal of immunopathology, molecular and cellular biology. 2017;84(1):16-24.
[16] van Heesbeen RG, Tanenbaum ME, Medema RH. Balanced activity of three mitotic motors is required for bipolar spindle assembly and chromosome segregation. Cell reports. 2014;8(4):948-956.
[17] Gayek AS, Ohi R. Kinetochore-microtubule stability governs the metaphase requirement for Eg5. Molecular biology of the cell. 2014;25(13):2051-2060.
[18] Tan LJ, Saijo M, Kuraoka I, Narita T, Takahata C, Iwai S, Tanaka K. Xeroderma pigmentosum group F protein binds to Eg5 and is required for proper mitosis: implications for XP-F and XFE. Genes to cells : devoted to molecular & cellular mechanisms. 2012;17(3):173-185.
[19] Wakana Y, Villeneuve J, van Galen J, Cruz-Garcia D, Tagaya M, Malhotra V. Kinesin-5/Eg5 is important for transport of CARTS from the trans-Golgi network to the cell surface. The Journal of cell biology. 2013;202(2):241-250.
[20] Liu M, Li D, Sun L, Chen J, Sun X, Zhang L, Huo L, Zhou J. Modulation of Eg5 activity contributes to mitotic spindle checkpoint activation and Tat-mediated apoptosis in CD4-positive T-lymphocytes. The Journal of pathology. 2014;233(2):138-147.
[21] Hayashi N, Koller E, Fazli L, Gleave ME. Effects of Eg5 knockdown on human prostate cancer xenograft growth and chemosensitivity. The Prostate. 2008;68(12):1283-1295.
[22] Rose AS, Bradley AR, Valasatava Y, Duarte JM, Prlic A, Rose PW. NGL viewer: web-based molecular graphics for large complexes. Bioinformatics (Oxford, England). 2018;34(21):3755-3758.
[23] Cochran JC, Gatial JE, 3rd, Kapoor TM, Gilbert SP. Monastrol inhibition of the mitotic kinesin Eg5. The Journal of biological chemistry. 2005;280(13):12658-12667.
[24] Garcia-Saez I, DeBonis S, Lopez R, Trucco F, Rousseau B, Thuery P, Kozielski F. Structure of human Eg5 in complex with a new monastrol-based inhibitor bound in the R configuration. The Journal of biological chemistry. 2007;282(13):9740-9747.
[25] Umbreit NT, Gestaut DR, Tien JF, Vollmar BS, Gonen T, Asbury CL, Davis TN. The Ndc80 kinetochore complex directly modulates microtubule dynamics. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(40):16113-16118.
[26] DeLuca KF, Meppelink A. Aurora A kinase phosphorylates Hec1 to regulate metaphase kinetochore-microtubule dynamics. 2018;217(1):163-177.
[27] Zhu T, Dou Z, Qin B, Jin C, Wang X, Xu L, Wang Z, Zhu L, Liu F, Gao X, Ke Y, Wang Z, Aikhionbare F, Fu C, Ding X, Yao X. Phosphorylation of microtubule-binding protein Hec1 by mitotic kinase Aurora B specifies spindle checkpoint kinase Mps1 signaling at the kinetochore. The Journal of biological chemistry. 2013;288(50):36149-36159.
[28] Tang NH, Toda T. MAPping the Ndc80 loop in cancer: A possible link between Ndc80/Hec1 overproduction and cancer formation. BioEssays : news and reviews in molecular, cellular and developmental biology. 2015;37(3):248-256.
[29] Alushin GM, Musinipally V, Matson D, Tooley J, Stukenberg PT, Nogales E. Multimodal microtubule binding by the Ndc80 kinetochore complex. Nature structural & molecular biology. 2012;19(11):1161-1167.
[30] Long AF, Udy DB, Dumont S. Hec1 Tail Phosphorylation Differentially Regulates Mammalian Kinetochore Coupling to Polymerizing and Depolymerizing Microtubules. Current biology : CB. 2017;27(11):1692-1699.e1693.
[31] Orticello M, Fiore M, Totta P, Desideri M, Barisic M, Passeri D, Lenzi J, Rosa A, Orlandi A, Maiato H, Del Bufalo D, Degrassi F. N-terminus-modified Hec1 suppresses tumour growth by interfering with kinetochore-microtubule dynamics. Oncogene. 2015;34(25):3325-3335.
[32] Ishikawa C, Senba M, Mori N. Mitotic kinase PBK/TOPK as a therapeutic target for adult Tcell leukemia/lymphoma. International journal of oncology. 2018;53(2):801-814.
[33] Yang YF, Pan YH, Cao Y, Fu J, Yang X, Zhang MF, Tian QH. PDZ binding kinase, regulated by FoxM1, enhances malignant phenotype via activation of beta-Catenin signaling in hepatocellular carcinoma. Oncotarget. 2017;8(29):47195-47205.
[34] Stauffer S, Zeng Y, Zhou J, Chen X, Chen Y, Dong J. CDK1-mediated mitotic phosphorylation of PBK is involved in cytokinesis and inhibits its oncogenic activity. Cellular signalling. 2017;39:74-83.
[35] Li Y, Yang Z, Li W, Xu S, Wang T, Wang T, Niu M, Zhang S, Jia L, Li S. TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun. Oncotarget. 2016;7(6):6748-6764.
[36] Liu Y, Liu H, Cao H, Song B, Zhang W, Zhang W. PBK/TOPK mediates promyelocyte proliferation via Nrf2-regulated cell cycle progression and apoptosis. Oncology reports. 2015;34(6):3288-3296.
[37] Shih MC, Chen JY, Wu YC, Jan YH, Yang BM, Lu PJ, Cheng HC, Huang MS, Yang CJ, Hsiao M, Lai JM. TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer. Oncogene. 2012;31(19):2389-2400.
[38] Hu F, Gartenhaus RB, Eichberg D, Liu Z, Fang HB, Rapoport AP. PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21. Oncogene. 2010;29(40):5464-5474.
[39] Nandi AK, Ford T, Fleksher D, Neuman B, Rapoport AP. Attenuation of DNA damage checkpoint by PBK, a novel mitotic kinase, involves protein-protein interaction with tumor suppressor p53. Biochemical and biophysical research communications. 2007;358(1):181-188.
[40] Ohashi T, Komatsu S, Ichikawa D, Miyamae M, Okajima W, Imamura T, Kiuchi J, Nishibeppu K, Kosuga T, Konishi H, Shiozaki A, Fujiwara H, Okamoto K, Tsuda H, Otsuji E. Overexpression of PBK/TOPK Contributes to Tumor Development and Poor Outcome of Esophageal Squamous Cell Carcinoma. Anticancer research. 2016;36(12):6457-6466.
[41] Seol MA, Park JH, Jeong JH, Lyu J, Han SY, Oh SM. Role of TOPK in lipopolysaccharide-induced breast cancer cell migration and invasion. Oncotarget. 2017;8(25):40190-40203.